<DOC>
	<DOCNO>NCT00555334</DOCNO>
	<brief_summary>The purpose investigator ' study prospectively evaluate whether nucleoid antiviral therapy improve outcome radiofrequency ablation hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Nucleoid Adjuvant Therapy After Radiofrequency Ablation Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Age 18 75 year , refuse surgery ; A solitary HCC ≤ 7.0cm diameter , multiple HCC ≤ 3 lesion , ≤ 3.0cm diameter Lesions visible ultrasound ( US ) acceptable/safe path lesion skin show US , No extrahepatic metastasis No image evidence invasion major portal/hepatic vein branch No history encephalopathy , ascites refractory diuretic variceal bleed A platelet count &gt; 40,000/mm3 No previous treatment HCC except liver resection . Patient compliance poor The blood supply tumor lesion absolutely poor arterialvenous shunt TACE perform Previous concurrent cancer distinct primary site histology HCC , EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat &gt; 3 year prior entry permit . History cardiac disease : congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 ; active coronary artery disease ( myocardial infarction 6 month prior study entry permit ) ; cardiac arrhythmia require antiarrhythmic therapy beta blocker , calcium channel blocker digoxin ; uncontrolled hypertension ( failure diastolic blood pressure fall 90 mmHg , despite use 3 antihypertensive drug ) . Active clinically serious infection ( &gt; grade 2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE ] version 3.0 ) Known history human immunodeficiency virus ( HIV ) infection Known Central Nervous System tumor include metastatic brain disease Patients clinically significant gastrointestinal bleeding within 30 day prior study entry Distantly extrahepatic metastasis History organ allograft Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Any condition unstable could jeopardize safety patient his/her compliance study Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within seven day prior start study drug . Both men woman enrol trial must use adequate barrier birth control measure course trial . Excluded therapy medication , previous concomitant : Prior use systemic anticancer treatment HCC , eg . chemotherapy , immunotherapy hormonal therapy ( except hormonal therapy supportive care permit ) . Antiviral treatment allow , however interferon therapy must stop least 4 week prior randomization . Prior use systemic investigational agent HCC Autologous bone marrow transplant stem cell rescue within four month start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>liver cancer</keyword>
	<keyword>radiofrequency ablation</keyword>
	<keyword>lamivudine</keyword>
</DOC>